◼ Archived
Business
🔮 Newsylist predicts: still trending tomorrow medium confidence — graded ✗ wrong
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
5sources
5articles
3velocity
+0%since first seen
3d agofirst detected
Text:
🤖 AI Dossier
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The reporting (5)
-
-
-
-
-
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere Fierce Biotech · 4d ago broke it first
📊 AUDIENCE & LONGEVITY PULSE
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Related trends
🔥 Breakout ↑ Rising
Business
Volkswagen's replacement for the ID.4 crossover is here
🔥 Breakout ↑ Rising
Business
8 hospitalized after severe turbulence forces New York City bound flight to divert to MIA, officials say
↑ Rising
Business
Exclusive: Apple cuts iPhone 18 Pro orders due to soft demand
▲ Peaking
Business
Oil eases, bringing some respite to stocks and battered bonds
↓ Cooling
Business
What smart people are saying about the US suspending PERM visas for Microsoft, Adobe, and Indian tech giants
↑ Rising
Business